(TESARO 4010-01-001) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Koenraad De Geest
This is a research study to test a new investigational drug. An investigational drug is one that is not yet approved by any regulatory authorities, such as the United States Food and Drug Administration (FDA). The investigational drug being studied here is called TSR-042, and is an anti-programmed cell death-1 (anti-PD-1) antibody, designed to help the immune system recognize and attack cancer cells.
This is a Phase 1 study that is being carried out in 3 parts; currently, the study is enrolling into the final stage, Part 2B, with a main purpose of evaluating the ability of the investigational drug to reduce the size of tumors in patients with specific cancer types, including endometrial cancer.
1. Histologically or cytologically proven advanced (unresectable) or metastatic endometrial cancer (all histologies are allowed except endometrial sarcoma)
2. Progression of disease on or after platinum doublet therapy, with no more than 2 lines of prior anti-cancer therapy (hormone therapies do not count toward this number) for recurrent or advanced (≥Stage IIIB) disease; evidence of progression by two radiographic imaging studies/scans must be available for submission to the study sponsor
3. Availability of formalin-fixed, paraffin-embedded archival tumor tissue from a previous surgery/biopsy; or, if unavailable, agreement to a new biopsy to obtain a tissue sample from an easily accessible tumor lesion prior to study treatment initiation
Other eligibility criteria will also apply.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Treatment can continue for up to 2 years, or until disease progression, unacceptable toxicity, patient withdrawal, investigator decision, or death. Continued treatment with the study drug beyond 2 years may be considered following discussion between the investigators and the study sponsor.
After treatment ends, you will be followed for safety assessments every 90 days via telephone.
Yukie Bean, CCRP
Gyn/Onc Study Coordinator